[Experimental and clinical results of a new anti-epileptic: sodium di-n-propyl acetate (DPA) specialized under the marketed name, Depakine. Second study].
D000085:Acetates / Q000008:administration & dosage* / Q000633:toxicity; D000293:Adolescent; D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage / Q000633:toxicity; D001519:Behavior / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy; D006801:Humans; D007223:Infant; D009207:Myoclonus / Q000188:drug therapy; D010433:Pentylenetetrazole / Q000633:toxicity; D011817:Rabbits
D000085:Acetates; D000927:Anticonvulsants; D010433:Pentylenetetrazole
Résultats expérimentaux et cliniques d'un nouvel anti-épileptique: di-n-propyl acétate de sodium (DPA) spécialisé sous la marque Dépakine. Deuxième étude.